Salary: Dependent on relevant Postdoctoral experience. Future progression is based on annual performance review. If the candidate has not yet been awarded their PhD, the starting salary will be at £32,844 until the successful completion of their viva.
Duration of Contract: Fixed Term until 31st July 2025
Research Lead: Professor Alan Melcher
We are seeking a creative and motivated Postdoctoral Training Fellow to develop oncolytic virus-based strategies for the treatment of breast cancer. The Melcher/Harrington lab has shown that some oncolytic viruses can be an effective cancer treatment in combination with other agents, particularly small molecule drugs used for the treatment of breast cancer (PARP inhibitors, CDK4/6 inhibitors). This position will build off this work to test the efficacy and immunogenicity of these strategies in breast cancer pre-clinical models. This will include both human and murine model systems, which are well established in the Breast Cancer Now Toby Robins Research Centre. This post will be strategically linked to Breast Cancer Now-funded research in immunology and immunotherapy at KCL, with which there will be close interaction.
This position is offered on a fixed term contract until July 2025 in the first instance. Starting salary is in the range of £32,844* to £41,718 per annum inclusive based on previous postdoctoral experience.
*thesis submitted, awaiting PhD award
The successful candidate must have a knowledge of cancer biology and cancer immunology together with a strong record in biomedical research as demonstrated by high-impact, first author publications in relevant areas.
The ICR has a workforce agreement stating that Postdoctoral Training Fellows can only be employed for up to 7 years as PDTF at the ICR, providing total postdoctoral experience (including previous employment at this level elsewhere) does not exceed 10 years
The Breast Cancer Immunology Team is led by Alan Melcher and looks at ways to activate the immune system to attack cancer using therapeutic oncolytic viruses, radiotherapy, targeted drugs and combination strategies. The agents we prioritise are already in clinical use and offer major potential benefits to further improve the promising field of immunotherapy. We use a range of mouse and human pre-clinical assays to test the immune response following our interventions.
The Breast Cancer Immunology team is part of the Division of Breast Cancer Research and sits within the Breast Cancer Now Toby Robins Research Centre at the ICR, the first centre in the UK entirely devoted to breast cancer research. Our goal is to advance research into the causes, diagnosis and treatment of breast cancer. The Breast Cancer Immunology team collaborates with the Breast Cancer Now Research Unit based at King’s College London (KCL).
We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Pip Wilkinson via email on email@example.com
About The Institute of Cancer Research
Why work for us?
As a member of staff, you’ll have exclusive access to a range of staff benefits.
The ICR is committed to supporting overseas applicants applying for roles, please click here to find out further information.
The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. Further information about working at the ICR can be found here.
We look forward to receiving applications from all candidates, wherever in the world they are currently based. We will select those who display the potential to become, or to support, the world leading cancer researchers of the future based on their application and performance at interview. However, we particularly welcome British applicants from black and ethnic minority backgrounds, as they are under-represented within the ICR and nationwide in STEM roles.